In summary, CRISPR editing in human HSPCs generates de novo (t;411) leukemia that captures the phenotypic, transcriptional, and chromatin accessibility signatures of human KMT2A-AFF1 BCP-ALL, highlighting the advantages of gene-edited cells for modeling human disease. Here, KMT2A is linked to acute lymphoblastic leukemia.